<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617526</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA806-201</org_study_id>
    <nct_id>NCT00617526</nct_id>
  </id_info>
  <brief_title>Naïve HIV POC Monotherapy Trial</brief_title>
  <official_title>A Multicenter Phase 2a, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is:

      • to evaluate the change from baseline in plasma viral load with placebo and one of up to 4
      dose regimens of RDEA806.

      The secondary objectives are:

      Efficacy

        -  to describe the nadir of the plasma viral load

        -  to describe the DAVG

        -  to assess the proportion of subjects who reached a drop in viral load of 0.5 log, 1 log,
           or reach an undetectable viral load

        -  to assess the plasma viral load decay rate

        -  to evaluate immunologic changes (as measured by CD4 and CD8 cells)

        -  to evaluate the genotypic and phenotypic pattern of the virus Pharmacokinetics

        -  to evaluate the pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of
           RDEA806 Safety

        -  to evaluate the safety and tolerability of bid and qd dosing of RDEA806 as monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HIV plasma viral load</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed as adverse and HIV related events, clinical laboratory test results(hematology, chemistry, urinalysis), vital signs, 12-lead electrocardiograms (ECGs), and physical examination</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Resistance</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>RDEA806 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA806 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA806 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA806 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA806 400 mg</intervention_name>
    <arm_group_label>RDEA806 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>RDEA806 400 mg</arm_group_label>
    <arm_group_label>RDEA806 600 mg</arm_group_label>
    <arm_group_label>RDEA806 800 mg</arm_group_label>
    <arm_group_label>RDEA806 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA806 1000 mg</intervention_name>
    <arm_group_label>RDEA806 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA806 600 mg</intervention_name>
    <arm_group_label>RDEA806 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA806 800 mg</intervention_name>
    <arm_group_label>RDEA806 800 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented chronic HIV-1 infection

          -  HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/ml

          -  Male, aged above 18 years and less than 65 years of age

          -  Adequate method of birth control

          -  Subject has never received an antiretroviral agent (NRTI, NNRTI, PI, entry inhibitor
             or integrase inhibitor) for the treatment of HIV and agrees not to start
             antiretroviral therapy prior to enrollment or subject has only received a short course
             of treatment for less than 14 days and has been off treatment for at least 8 weeks

          -  Subject has no primary mutation in the reverse transcriptase (RT) gene associated with
             resistance to RT inhibitors and no major mutation in the protease gene associated with
             resistance to PIs determined by genotypic resistance testing at screening

        Exclusion Criteria:

          -  History or suspicion of alcohol or drug abuse which in the Investigator's opinion may
             lead to non-compliance

          -  CD4 count &lt; 350 cells/mm3

          -  Life expectancy of less than 6 months

          -  Receipt of an investigational drug within 30 days prior to the trial drug
             administration

          -  Receipt of any vaccine within 30 days of screening visit

          -  Acute HIV-1 infection (seroconversion illness)

          -  Acute hepatitis A or acute or chronic hepatitis B or C infection

          -  Currently active acquired immune deficiency syndrome (AIDS)-defining illness (Category
             C conditions according to the Centers for Disease Control [CDC] Classification System
             for HIV Infection 1993)

          -  No clinically relevant laboratory abnormalities Renal impairment: serum creatinine &gt;
             1.5 x ULN

          -  Febrile illness within 120 hours prior to dosing

          -  History of severe drug allergy or hypersensitivity

          -  Significant cardiac dysfunction
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Hingorani, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW109NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <disposition_first_submitted>October 29, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 29, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 21, 2013</disposition_first_posted>
  <last_update_submitted>December 20, 2013</last_update_submitted>
  <last_update_submitted_qc>December 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>treatment naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

